TG and metabolic dysfunction-associated steatohepatitis: There is new hope with the recent approval by the FDA of the thyroid hormone agonist resmetirom (RezdiffraTM), which reduces fibrosis in MASH and reduces MASH without increasing fibrosis, but optimism is tempered by an improvement in only 50% of patients in Phase III trials [51].